Patent ID: 11883428
Assignee: LPOXY THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. An oral formulation in solid form for treating an intestinal anaerobic bacterial infection, comprising:
an agent, a catalyst, a first controlled release coating encasing the agent, a second controlled release coating encasing the catalyst and the encased agent, a porous membrane that encapsulates the catalyst and the encased agent, and an enteric coating surrounding the oral formulation,
wherein the agent comprises sodium percarbonate or carbamide peroxide,
wherein the catalyst comprises catalase,
wherein the catalase controls the rate of conversion of the agent to oxygen,
wherein the porous membrane comprises at least two or more layers made of one or more of: cellulose propionates, cellulose acetate butyrates, cellulose acetate acetoacetate, cellulose chloroacetate, cellulose acetate furoate, dimethoxyethyl cellulose acetate with a functional pore size that prevents a majority of the catalyst from diffusing across the membrane,
wherein the functional pore size is smaller than an actual pore size,
wherein the pore size is sufficient to allow water to diffuse across any portion of the membrane to contact the agent and to allow oxygen to diffuse across any portion of the membrane into an intestine of the subject, wherein when orally administered to a subject, the agent provides 2-5% of said oxygen in at least a portion of the intestine for 24 hours or more to create an aerobic environment in the intestine sufficient to inhibit growth of a population of anaerobic bacteria that caused an anaerobic bacterial infection in the intestine,
and wherein the oral formulation is in a solid form as a pill or a capsule.